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ABSTRACT:
Aneuploidy plays an important role in the development of cancer. Here, we 
uncovered an oncogenic role for geminin in mitotic cells. In addition to chromatin, 
tyrosine phosphorylated geminin also localizes to centrosome, spindle, cleavage 
furrow and midbody during mitosis. Geminin binding to Aurora B prevents its 
binding to INCENP, and thus activation leading to lack of histone H3-(serine 10) 
phosphorylation, chromosome condensation failure, aborted cytokinesis and the 
formation of aneuploid, drug resistance cells. Geminin overexpressing human 
mammary epithelial cells form aneuploid, aggressive tumors in SCID mice. Geminin 
is overexpressed in more than half of all breast cancers analyzed. The current 
study reveals that geminin is a genuine oncogene that promotes cytokinesis 
failure and production of aneuploid, aggressive breast tumors when overexpressed 
and thus a worthy therapeutic target (oncotarget) for aggressive breast cancer.
 INTRODUCTION
Cytokinesis failure (aka cytokinesis skipping) leads 
to tetraploidy/aneuploidy and tumor formation [1-3]. 
Cytokinesis failure can arise from defects in the cleavage 
apparatus, chromosome bridging, merotelically-attached 
chromosomes lodged in the cleavage furrow, spindle 
malorientation and defective midbody abscission [1]. 
During abscission, the last phase of cytokinesis, 
dividing cells are separated into two daughter cells [4]. 
NoCut is a phenotype in budding yeast where Ip1, the 
Aurora B (AurB) homolog, delays abscission in response 
to mid-spindle defects. In human cells, AurB is essential 
for chromosome condensation, segregation, furrow 
ingression, as well as cytokinesis [5], suggesting that 
NoCut might be related to abscission failure in human 
cells [6]. 
During mitosis AurB form a complex with INCENP, 
survivin, and borealin named chromosomal passenger 
complex [CPC, 7,8]. INCENP interaction with AurB in 
vivo triggers AurB autophosphorylation, modulates the 
level of kinase activity and regulates CPC localization 
and function during mitosis [8]. Indeed, CPC regulates 
various mitotic processes and functions to maintain 
genomic stability [9]. AurB controls these processes 
by phosphorylating a large number of substrates, such 
as histone H3-(S10) and mitotic kinesin-like protein 1 
[Mklp1, 6]. Interestingly, microinjection of INCENP 
blocking antibody in early mitosis forced mitotic exit 
without the execution of cytokinesis and triggered 
formation of aneuploid cells [10]. 
Geminin is a multifunctional protein. Geminin binds 
to Cdt1 at ORIs and prevents recruitment of the MCM2-
7 complex and thus inhibits DNA replication [11,12]. 
Geminin antagonizes the transcriptional activity of Six3 
and HoxB9 [13,14]. Geminin coordinates proliferation 
and differentiation in the nervous system by assisting 
transcriptional modulators, such as polycomb and SWI/
SNF in the control of cell cycle progression, chromatin 
organization, and transcription [15]. Geminin modulates 
T-cell proliferation and expansion during the immune 
response, but not progenitor T-cell commitment and 
differentiation in the immune system [16]. Geminin 
suppresses the large-scale chromatin de-condensation Oncotarget 2011; 2:  1011 - 1019 1012 www.impactjournals.com/oncotarget
induced by Cdt1/MCM in G1-phase [17]. Finally, Geminin 
regulates pluripotent cells self-renewal, since its’ silencing 
suppressed expression of the self-maintenance proteins, 
Oct4, Sox2 and Nanog and loss of stem cell identity [18]. 
However, geminin silencing in Xenopus embryos 
[19], human mammary epithelial (HME) cells [20] or 
knockout mice [21] did not induce massive re-replication 
but prevented mitosis entry/exit, suggesting an essential 
mitotic function as well for geminin. Indeed, we recently 
showed that geminin interacts with topoisomerase II 
alpha (TopoIIα) on chromosomes in G2/M/early G1 cells 
[22]. Geminin silencing in HME cells prevented TopoIIα 
accumulation on chromosomal arms and led to formation 
of chromosome bridges that arrested cells at cytokinesis 
[22]. In vivo, at normal concentration, geminin recruits 
the deSUMOylating enzymes SENP1 and SENP2 to 
deSUMOylate chromosomal bound TopoIIα and induces 
its timely release from chromosomes after completion of 
chromosome decatenation [22]. At higher concentrations, 
however, geminin recruits more deSUMOylating 
enzymes, or recruits them earlier to chromosomal bound 
TopoIIα  and  prematurely  inactivates  it  and  generates 
chromosome breakages [22]. These breakages were not 
sensed or repaired and the cell cycle was not arrested 
in geminin overexpressing cells leading to formation of 
aneuploid, drug resistant cells [22].
Here, we show that geminin is localized to 
centrosomes, spindle, cleavage furrow and midbody 
during G2/M/early G1 in HME cells. In vivo, geminin 
overexpression inactivated Aurora B (AurB) by 
preventing its binding to INCENP. Therefore, geminin-
overexpressing cells showed lack of histone H3-
Figure 1: Geminin localization in HME cells. Localization of geminin (green) and γ-tubulin (red) in interphase (A), metaphase (B) 
and in cytokinesis (C and D) in HME cells. Blue is DAPI-stained DNA. (E) Expression of Myc-tagged WT or Y-to-A geminin variants 
in HME cells. (F) Expression of His-tagged WT (Gem9) or Y-to-A mutant geminin variants in nuclear soluble or chromatin HME cells 
fractions. (G-V) Localization of endogenous geminin (green) and Myc-tagged exogenous geminin variants (red) in HME cells. Blue is 
DAPI stained DNA.  Oncotarget 2011; 2:  1011 - 1019 1013 www.impactjournals.com/oncotarget
(S10) phosphorylation, chromosome decondensation, 
cytokinesis skipping and formation of tetraploid/aneuploid 
cells. These cells also showed multiple centrosomes and 
were multi-nucleated. Geminin overexpressing HME 
cells developed subcutaneous and mammary tumors in 
SCID mice that also contained many aneuploid cells. 
Geminin is overexpressed in ~50% of all breast tumor 
samples analyzed, especially Her2 overexpressing 
(Her2+) and triple negative/basal like (TN/BL) tumors, 
and its overexpression is associated with poor prognosis 
and outcome. Our data show that geminin controls 
cytokinesis in human cells, preciously abscission, that 
geminin is a genuine breast cancer oncogene that induces 
tetraploidy/aneuploidy when overexpressed by inhibiting 
AurB, that this mechanism contributes to the induction of 
aneuploid, aggressive and metastatic breast tumors, and 
that therapeutic targeting of geminin might be pursued to 
inhibit breast cancer metastasis.
RESULTS
Geminin localization during G2/M/early G1 in 
HME cells
Geminin silencing in HME cells arrests cytokinesis 
with little effect on S phase progression [20]. To expand 
these results, we sought evidence of geminin localization 
in G2/M/early G1 HME cells. Synchronized HME cells in 
different part of the cell cycle were immunostained with 
anti-γ-tubulin (red) and -geminin (green). We found that 
geminin was localized with γ-tubulin to centrosome in late 
interphase (Figure 1A), spindle in metaphase (Figure 1B), 
cleavage furrow and midbody in cytokinesis (Figure 1C 
and D). 
Geminin is a serine/threonine (S/T) phosphorylated 
soluble protein in S-phase, and a tyrosine (Y) 
phosphorylated chromatin bound protein in G2/M/early G1 
phase [20]. Geminin contains three Y residues, at positions 
98, 111 and 150. Using site directed mutagenesis, each Y 
was separately mutated to alanine (A) or phenylalanine 
(F, throughout the paper, identical data were obtained with 
the Y-to-F mutants). Wild type (WT) and mutant cDNAs 
were cloned into a vector that introduces a Myc tag 
upstream of each protein. Anti-Myc immunoblotting on 
sonicated extracts of transiently transfected (48h) HME 
cells showed that all proteins were expressed at similar 
levels (Figure 1E). WT and mutant cDNAs were also 
cloned into a vector that puts expression of all cDNAs 
under a doxycycline inducible promoter and introduces a 
His tag downstream of each protein. Inducible cell lines 
were generated (2 WT cell lines Gem9 and Gem10 were 
chosen to analyze further in this study. Please note that 
throughout the paper analysis of another doxycycline 
inducible clone “Gem10” gave identical results to 
clone Gem9). Anti-His immunoblotting on 72h induced 
(with 2µg/ml doxycycline, Dox) WT (hereafter Gem9), 
GemY98A, GemY111A or GemY150A cells showed 
that all proteins like endogenous geminin are located in 
the soluble nuclear fraction in S phase cells, while on the 
chromatin in M/G1 phase cells (see [20] and Figure 1F).
To study the effect of geminin Y phosphorylation 
on protein localization in G2/M/early G1 cells, HME 
cells were transiently transfected with Myc-tagged WT, 
Y98A, Y111A or Y150A cDNAs. Forty-eight hours 
later cells were immunostained with anti-geminin (to 
detect endogenous protein, green) and anti-Myc (to 
detect exogenous proteins, red) antibodies. Exogenous 
WT (Figure 1E-H) and not Y98A (Figure 1K-N), Y111A 
(Figure 1O-R) or Y150A (Figure 1S-V) geminin was 
co-localized with endogenous geminin at the cleavage 
furrow, centrosome, spindle and midbody localization 
(data not shown). Taken together, these data show that 
while geminin Y phosphorylation on all tyrosine residues 
in the same time is not required for protein nuclear and 
chromatin localization, it is absolutely required for protein 
localization to centrosome, spindle, cleavage furrow and 
midbody in G2/M/early G1 cells. It is possible that Y 
phosphorylation activates geminin proposed cytokinetic 
function [20]. 
Geminin overexpression suppresses H3-(S10) 
phosphorylation and promotes tetraploidy/
aneuploidy in HME cells
The majority of geminin silenced cells were 
positive for the mitotic marker p-(S10)-H3 and arrested 
at cytokinesis [20]. First, to examine the effect of Y 
phosphorylated/activated geminin overexpression on H3-
(S10) phosphorylation, Gem9, GemY98A, GemY111A 
and GemY150A cells were grown in the presence of 2µg/
ml Dox (hereafter induced) for 96h. Aliquots were then 
labeled with FITC-p-H3(S10) antibody or FITC-IgG 
(same isotype) and analyzed by FACS. Control HME cells 
showed 14±2% p-(S10)-H3-positive cells (Figure 2A). 
Induced Gem9 cells showed 2.5±0.5% (p-value=0.005, 
Figure 2B), induced GemY98A showed 11.4±4% (p=0.4, 
Figure 2C), induced GemY111A showed 15.6±2% (p=0.8, 
Figure 2D) and induced GemY150A showed 9.7±5% 
(p=0.06, Figure 2E) p-(S10)-H3-positive cells.
Second, to investigate the effect of overexpressing 
Y phosphorylated/activated geminin on ploidy, Gem9, 
GemY98A, GemY111A and GemY150A were induced for 
48h followed by addition of Aphidicoline (1µg/ml, Aph) 
to cells for another 24h. After washing off the Aph, cells 
were incubated with 20µM of BrdU for an additional 24h. 
Cells were then labeled with FITC anti-BrdU antibody 
and propidium iodine (PI) and analyzed by FACS. In 
control uninduced Gem9 3±1% cells showed >4N DNA 
content (Figure 2F). In induced Gem9 35±5% (p=0.0014, Oncotarget 2011; 2:  1011 - 1019 1014 www.impactjournals.com/oncotarget
Figure 2: Analysis of histone H3 phosphorylation and ploidy in HME cells overexpressing WT or Y-to-A mutants 
geminin. (A-E) The p-(S10)-H3 expressing populations (percentages are shown, blue lines) in HME, and induced (96h) Gem9, GemY98A, 
GemY111A and GemY150A cells were measured by FACS. Data are compared to same IgG isotype (red lines). Results represent one of the 
experiments performed 3 times in triplicates. (F-J) Cell cycle analysis of uninduced Gem9 or induced (96h) Gem9, GemY98A, GemY111A 
and GemY150A cells as described in text. Tetraploid/aneuploid populations (percentages are shown) were measured by FACS (see red 
circles). R1=G0/G1, R3/R4/R5=early/mid/late S, R2=G2/M and R6=>4N cells. Results represent one of the experiments performed 3 times 
in triplicates.
Figure 3: Tyrosine mutant geminin variants are apoptosis instead of tetraploidy/aneuploidy inducers. (A) Cell cycle 
analysis of HME and induced (96h) Gem9, GemY98A, GemY111A and GemY150A cells. HME and Gem9 cells were also transfected with 
luciferase or geminin siRNA during the last 72h. Cell cycle profiles (percentages are shown) were measured by FACS. Results represent 
the means ± SD of experiments performed 3 times in triplicates. Inset shows the knockdown effect of geminin siRNA in HME and induced 
Gem9 cells. (B) TUNEL analysis performed on HME and induced (96h) Gem9, GemY98A, GemY111A and GemY150A cells. (C) Number 
of apoptotic cells (TUNEL-positive) per field in cultures in (B). Results represent the means ± SD of experiments performed 3 times in 
triplicates, ** = p≤0.01. (D) Expression of geminin and pro-survival proteins in sonicates (total cellular proteins) of HME and induced (96) 
Gem9, GemY98A, GemY111A and GemY150A. (E) Phase contrast images of HME and induced (168h) Gem9, GemY98A, GemY111A 
and GemY150A. Images represent one of the experiments performed 3 times in triplicates. Oncotarget 2011; 2:  1011 - 1019 1015 www.impactjournals.com/oncotarget
Figure 2G), in induced GemY98A 4±1% (p=0.3, Figure 
2H), in induced GemY111A 11±4% (p=0.4, Figure 2I) 
and in induced GemY150A 5±2% (p=0.5, Figure 2J) cells 
showed >4N DNA content. Taken together, these data 
suggest that overexpression of Y phosphorylated/activated 
geminin suppresses phosphorylation of (S10)-H3 and 
triggers tetraploidy/aneuploidy in HME cells, perhaps 
through promoting cytokinesis skipping. 
Tyrosine mutant geminin induces apoptosis 
instead of tetraploidy/aneuploidy in HME cells
To confirm that these are indeed geminin-dependent 
effects, HME, Gem9, GemY98A, GemY111A and 
GemY150A cells were grown in the presence of Dox for 
96h. HME and Gem9 cells were also transfected with 
luciferase  (control)  or  geminin  specific  siRNA  during 
the last 72h. Aliquots of each culture were labeled with 
PI  and  cell  cycle  profile  was  measured  using  FACS. 
Gem9 cells growing in Dox express 3-4fold geminin 
above endogenous level in HME cells growing in Dox, 
and  geminin  siRNA  significantly  suppressed  geminin 
expression in both cell lines (Figure 3A, inset).
In line with our previous data [20], geminin-
silencing arrested HME cells in G2/M phase (Figure 3A, 
left). WT geminin overexpression accelerated the cell 
cycle instead (see also [23]) and triggered formation 
of cells with >4N DNA content (Figure 3A, middle). 
Geminin silencing in induced Gem9 cells restored normal 
cell cycle progression and prevented the formation of cells 
with >4N DNA content (Figure 3A, middle). Meanwhile, 
induced GemY98A, GemY111A or GemY150A cells 
showed  near  normal  cell  cycle  profile,  and  had  low 
number of cells with >4N DNA content, but showed high 
numbers of sub-G1 (i.e. dying) cells (Figure 3A, right). 
Taken together these data suggest that overexpression of 
Y phosphorylated/activated geminin induces tetraploidy/
aneuploidy, whereas overexpression of tyrosine mutant 
geminin induces cell death instead. 
To investigate that further, induced (48h) Gem9, 
GemY98A, GemY111A and GemY150A cells were 
labeled with annexin V/PI and analyzed by FACS. 
Control HME cells showed 81% live (i.e. PI-/V-), 12% 
necrotic (i.e. PI+/V-) and 7% apoptotic (i.e. PI-/V+ + PI+/
V+) cells (Suppl. Figure 1A). Induced Gem9 cells showed 
89% PI-/V- (p<0.05), 7% PI+/V- (p<0.05), and 4% PI-/V+ 
+ PI+/V+ (p<0.5) cells (Suppl. Figure 1B). Meanwhile, 
induced GemY98A showed 61% PI-/V- (p<0.05), 30% 
PI+/V- (p<0.05) and 9% PI-/V+ + PI+/V+ (p<0.05) cells 
(Suppl. Figure 1C), induced GemY111A showed 40% PI-
/V- (p<0.05), 51% PI+/V- (p<0.05), and 9% PI-/V+ + PI+/V+ 
(p<0.05) cells (Suppl. Figure 1D) and induced GemY150A 
showed 67% PI-/V- (p<0.05), 24% PI+/V- (p<0.05) and 9% 
PI-/V+ + PI+/V+ (p<0.05) cells (Suppl. Figure 1D).
TUNEL analysis on induced (96h) Gem9, GemY98A, 
GemY111A and GemY150A cells showed that compared 
to control HME cells that had 9±2 TUNEL-positive cells/
filed, induced Gem9 cells had only 4±1 TUNEL-positive 
cells/field  (p<0.05, Figure 3B and 3C). Meanwhile, 
induced GemY98A showed 53±5 (p<0.05), GemY111A 
72±8 (p<0.05) and GemY150A 47±6 (p<0.05) TUNEL-
positive cells/field (Figure 3B and 3C). 
To analyze that on a molecular level, induced (96h) 
Gem9, GemY98A, GemY111A and GemY150A cells 
were sonicated and whole cell extracts were analyzed 
for the expression of several pro-survival proteins with 
immunoblotting. Compared to control HME cells, high 
expression levels of the pro-survival proteins, Bcl-
2, Bcl-xL and p-Bad in induced Gem9 cells, whereas 
lower expression (even below HME levels) of these 
proteins in all mutant cell lines was detected (Figure 3D). 
Consistently, low but detectable level of cleaved PARP 
(an early sign of apoptosis) was detected in HME cells, 
no such cleavage was detected in induced Gem9 cells, but 
high levels of cleaved PARP were detected in all mutant 
cell lines (Figure 3D).
Indeed, when we induced 5000 Gem9, GemY98A, 
GemY111A or GemY150A cells for 168h, we found that 
compared to HME (also plated at 5000 cells), prolonged 
overexpression of wild type geminin dramatically increased 
the number of cells (Figure 3E, see also Montanari et al., 
2005). Meanwhile prolonged overexpression of any of the 
Y mutants virtually killed all the cells (Figure 3E). Overall, 
these data show that overexpression of Y phosphorylated/
activated geminin triggers formation and survival of 
tetraploid/aneuploid cells, and that mutating any of the 
three Y residues in geminin converts the overexpressed 
protein to death-inducer protein, instead. 
Geminin overexpression induces chromosome 
decondensation, centrosome multiplication, 
multi-nucleation and aborted cytokinesis
Diminution of (S10)-H3 phosphorylation leads 
to chromosome condensation failure [24]. To study 
whether overexpression of Y phosphorylated/activated 
geminin inhibits normal chromosome condensation, 
induced (96h) Gem9, GemY98A, GemY111A and 
GemY150A cells were exposed to 10µM of colcemid 
(a microtubules depolymerizing agent that arrests cells 
in metaphase) during the last 2h, then were processed 
to metaphase-spread, PI labeled and analyzed under 
microscope. Chromosomes were condensed in HME and 
induced GemY98A, GemY111A or GemY150A cells 
by this treatment (Figure 4A/1 and data not shown). In 
contrast, in induced Gem9 cells chromosomes were de-
condensed (Figure 4A/2), suggesting that overexpression Oncotarget 2011; 2:  1011 - 1019 1016 www.impactjournals.com/oncotarget
Figure 4: The effect of geminin overexpression on chromosome condensation, centrosome number, cytokinesis, ploidy 
and transformation in HME cells, in vitro. (A) Representative images of PI stained metaphase spreads of uninduced (1) or induced 
(96h, 2) Gem9 cells. Experiments were performed 3 times in triplicates and at least 100 cells per culture were analyzed. (B) Representative 
images of γ-tubulin labeled cells of uninduced (1) or induced (96h, 2) Gem9 cells. Arrows show the number of centrosomes in each cell. 
Experiments were performed 3 times in triplicates and at least 100 cells per culture were counted. (C) Representative images of γ-tubulin 
labeled cells in uninduced (1) or induced (96h, 2) Gem9 cells. Arrows show the number of nuclei in each cell. Experiments were performed 
3 times in triplicates. (D) Quantitative analysis of percentage of cells showing multiple centrosome (red bars), multi-nucleation (white 
bars) and cells aborting cytokinesis (black bars). Results represent the means ± SD of experiments performed 3 times in triplicates, ** = 
p≤0.01. (E) Time-lapse analysis of induced Gem9 cells (14 days). Cell “A” divided normally into 2 daughter cells, whereas cells “1, 2 and 
3” attempted to undergo cytokinesis but failed and became tetraploid. Images correspond to Suppl. movie 1. (F) Giemsa stained metaphase 
chromosomes of Gem9 grown in the absence (1 and 3) or presence (2 and 4) or 2µg/ml of Dox for 8 weeks. Experiments were performed 
3 times in triplicates and at least 100 cells per culture were counted. (G) Representative images of soft agar colony formation assay using 
uninduced (1) or induced Gem9 (2) cells. Experiments were performed 3 times in triplicates and at least 100 cells per culture were counted. 
(H) Quantitative analysis of the soft agar experiment described in (G). Data are represented as mean ± SD. *** = p<0.001.Oncotarget 2011; 2:  1011 - 1019 1017 www.impactjournals.com/oncotarget
of Y phosphorylated/activated geminin suppresses 
chromosome condensation (i.e. induces G2 arrest) or 
promotes premature chromosome de-condensation (i.e. 
accelerates M-to-G1 transition). We favor the latter because 
close examination of the chromosomes in colcemid treated 
induced Gem9 cells revealed that they resemble G1 and 
not G2/M chromosomes (see Figure 4A/2). 
Aneuploidy is usually associated with centrosome 
multiplication and leads to multi-nucleation. To test 
whether overexpression of Y phosphorylated/activated 
geminin promotes centrosome multiplication and/or multi-
nucleation, induced (96h) Gem9, GemY98A, GemY111A 
and GemY150A were immunostained with anti-γ-tubulin 
(a centrosome and cell body marker) then analyzed under 
microscope. Compare to interphase HME (i.e. Gem9-
Dox) cells that contained single centrosome (Figure 4B/1), 
induced Gem9 cells contained multiple (2-8) centrosomes 
(Figures 4B/2). No such centrosome multiplication 
was detected in induced GemY98A, GemY111A or 
GemY150A cells. Quantitatively, 1±0.5% control, 32±3% 
(p<0.01) induced Gem9, 4±0.5% (p<0.01) GemY98A, 
3±0.5% (p<0.01) GemY111A and 6±0.5% (p<0.01) 
GemY150A interphase cells had multiple centrosomes 
(Figure 4D). Moreover, none of control cells (Figure 4C/1 
and 4D), 26±5% induced Gem9 cells (p<0.01, Figure 
4C/2 and 4D), 3±0.5% induced GemY98A cells (p<0.01), 
5±0.5% induced GemY111A cells (p<0.01) and 4±0.5% 
induced GemY150A cells (p<0.01) interphase cells were 
multi-nucleated (Figure 4D). 
Finally, time-lapse analysis revealed that compared 
to only 1±0.5% of control uninduced Gem9 cells, 
384% of induced (96) Gem9 cells attempted to undergo 
cytokinesis but aborted and became tetraploid/aneuploid 
(Figure 4D and see example cells labeled 1, 2 and 3 in 
Figure 4E and compare that to cell labeled A in Figure 
4E and Suppl. movie #1). Meanwhile, 5±0.5% induced 
GemY98A, 4±0.5% induced GemY111A and 6±0.5% 
induced GemY150A aborted cytokinesis (Figure 4D). 
Overall, these data suggest that overexpression of Y 
phosphorylated/activated geminin induces cytokinesis 
skipping, centrosome multiplication, multi-nucleation and 
the production of tetraploid/aneuploid cells. 
Geminin overexpression induces aneuploidy and 
transformation in HME cells
To directly show that geminin overexpression induces 
aneuploidy in HME cells, we performed metaphase 
spread analysis on long time (8 weeks) uninduced (Gem9-
Dox) or induced (Gem9+Dox) cultures. Giemsa stained 
chromosomes were counted in at least 100 cells. Only 
1±0.5% of the uninduced Gem9 cells were aneuploid 
(see example in Figure 4F/1 and /3), whereas 36±7% of 
induced Gem9 cells were aneuploid (p<0.5, see example 
in Figure 4F/2 and 4). To assess whether this triggers 
transformation in HME cells, HME and Gem9 cells were 
Figure 5: Geminin overexpression inactivates AurB. Expression of several proteins in sonicates of HME and induced (96) Gem9, 
GemY98A, GemY111A and GemY150A cells. Note that because the same extracts were used to run the immunoblotting experiments 
described here and those in Figure 3D, geminin and actin blots are used in both figures. (B) Expression of several proteins in uninduced 
(-) or induced (+) Gem9 cells (left). Immunoprecipitated AurB from uninduced (-) or induced (+) Gem9 cells (right, upper) was used 
to in vitro phosphorylate GST-H3 (IVK, right). (C) Phosphorylation of survivin on T117 in uninduced (left) or induced (right) Gem9 
cells (right, lower). (D) Immunoprecipitating of AurB from HME or induced Gem9 cells using AurB or INCENP specific antibody. (E) 
Immunoprecipitating AurB from G1/S, G2/M or M/G1 HME cells using AurB or geminin specific antibodies. (F) The effect of AurB 
inhibitor ZM447493 on HME or induced Gem9 cell cycle progression. Results represent the means ± SD of experiments performed 3 times 
in triplicates, *= p<0.05 and ** = p<0.001.Oncotarget 2011; 2:  1011 - 1019 1018 www.impactjournals.com/oncotarget
grown in the presence or absence of Dox (72h) before they 
were layered on soft agar for an additional 14 days also in 
the presence or absence of Dox. Only few, small colonies 
were detected in HME and uninduced Gem9 cells at the 
end of the 14 days (Figure 4G/1 and 4H), whereas massive 
numbers of large size colonies were detected in induced 
Gem9 cultures (Figure 4G/2 and 4H). Taken together, it 
is clear that overexpression of Y phosphorylated/activated 
geminin triggers formation of multiple centrosomes, multi-
nucleation, tetraploidy/aneuploidy and transformation in 
HME cells.
Geminin overexpression triggers formation of 
tetraploid/aneuploid cells via AurB inhibition
AurB phosphorylates and activates a large number 
of proteins involved in chromosome condensation, 
segregation and cytokinesis, including (S10)-H3 
(Wheatly, 2011). The lack of p-(S10)-H3 in induced Gem9 
cells (Figure 2) made us wonder whether AurB is inactive 
in geminin overexpressing cells. Induced (96h) Gem9, 
GemY98A, GemY111A and GemY150A were sonicated 
and total cellular proteins were processed for western 
analysis. All cell lines showed equally high expression of 
WT or mutant geminin (3-4fold above endogenous level 
when induced, Figure 5A). While the expression of total 
AurB was equally high in HME and all induced cell lines, 
p-T232-AurB was virtually absent from induced Gem9, 
although HME control and all mutant cell lines showed 
high levels of it (Figure 5A). Because these are sonicated 
extracts (i.e. all cellular proteins are present), we propose 
that overexpression of Y phosphorylated/activated 
geminin inactivates AurB and not simply mislocalizes the 
protein in the cell.
To  confirm  that  further,  Gem9  cells  were  grown 
in the absence or presence of 2µg/ml Dox for 96h 
followed by sonication. Immunoblotting analysis 
showed 3-4fold increase in geminin level in induced 
compared to uninduced Gem9 cells (Figure 5B, left). 
Again, while expression of total AurB was not affected 
by geminin overexpression, virtually no p-T232-AurB 
was detected in induced compared to uninduced Gem9 
cells (Figure 5B, left). Moreover, using AurB antibody 
we immunoprecipitated equal amounts of total AurB from 
uninduced and induced Gem9 cells (Figure 5B, right). 
However, only AurB immunoprecipitated from uninduced 
Gem9 cells was able to phosphorylate GST-H3 in in vitro 
kinase (IVK) assay (Figure 5B, right). In addition, using 
a  phospho-specific  antibody,  we  showed  that  T117  on 
survivin (another target of AurB, [25]) was phosphorylated 
in uninduced (Figure 5C, left) but not induced Gem9 cells 
(Figure 5C, right). Taken together, these data confirm our 
hypothesis that AurB is inactivated in cells overexpressing 
Y phosphorylated/activated geminin. 
Possible mechanism for AurB inactivation in 
geminin overexpressing cells
A pre-requisite for AurB autophosphorylation and 
activation, in vivo is the binding to INCENP. To study 
whether overexpression of Y phosphorylated/activated 
geminin inactivates AurB by preventing it’s binding to 
INCENP, we attempted to immunoprecipitate AurB from 
HME or induced Gem9 (96h) G2/M cells using AurB or 
INCENP specific antibodies. While AurB and INCENP 
antibodies immunoprecipitated equal levels of AurB 
from HME G2/M cells (Figure 5D), from induced Gem9 
G2/M cells, only AurB antibody immunoprecipitated 
AurB. Moreover, geminin antibody immunoprecipitated 
AurB from G2/M only (Figure 5E), even-though AurB 
antibody immunoprecipitated AurB from HME in G1/S, 
G2/M and M/G1 phase (Figure 5E). These data show 
that overexpressed Y phosphorylated/activated geminin 
perhaps competes with INCENP for AurB binding, thus 
preventing AurB autophsophorylation and activation, in 
vivo.
Geminin overexpression induces resistance to 
AurB inhibitor, ZM447439 in HME cells
Since AurB is inactive in Y phosphorylated/
activated geminin overexpressing cells, we expected 
that AurB inhibitors would have no efficacy in geminin 
overexpressing cells. To study that in details, HME 
(or Gem9-Dox) and induced (72h) Gem9 cells were 
incubated with 5µM of ZM447439 (a specific and potent 
inhibitor of AurB) for an additional 24h. To measure the 
effect of ZM447439 on cell cycle progression aliquots 
from each culture were labeled with PI and analyzed 
by FACS. Compared to DMSO (control) treated cells, 
ZM447439 triggered accumulation of normal HME cells 
in G2/M phase followed by tetraploidy and then cell death 
(Figure 5F), whereas the same treatment had little effect 
on geminin overexpressing cells (Figure 5F). 
To measure the effect on ZM447439 on cell survival 
aliquots from each culture were labeled with PI/annexin 
V and analyzed by FACS. In DMSO (control) treated 
Gem9-Dox cells, 71±4% were alive (PI-/V-), 19±5% were 
necrotic (PI+/V-) and 10±3% were apoptotic (PI-/V+ + PI+/
V+) cells (Suppl. Figure 2A), and ZM447439 treatment 
significantly increased cell death in the uninduced Gem9 
cells. Indeed, in ZM447439 treated cells only 40±5% of 
the cells were PI-/V-, and 41±7% were PI+/V- and 20±6% 
were PI-/V+ + PI+/V (Suppl. Figure 2B). In contrast, in 
DMSO treated Gem9+Dox, 79±3% were PI-/V-, 16±2% 
were PI+/V- and 5±2% were PI-/V+ + PI+/V+ cells, and 
ZM447439 treatment did not significantly increase cell 
death in these induced Gem9 cells. Indeed, in ZM447439 
treated cells 66±4% of the cells were PI-/V-, 24±3% were 
PI+/V- and 10±3% were PI-/V+ + PI+/V+ (Suppl. Figure 2E). Oncotarget 2011; 2:  1011 - 1019 1019 www.impactjournals.com/oncotarget
Figure 6: Generation and analysis of geminin overexpression-induced tumors. (A) Volume of subcutaneous tumors developed 
in mice (10 mice/group) injected with HME/TERT, HME/TERT/LT, HME/TERT/geminin (i.e. Gem9), or HME/TERT/LT/geminin (i.e. 
Gem9/LT) cells. Representative H&E stained sections, in which Gem9/LT tumors invading mouse muscle (see M in B), bone (see B in 
C), skin (see S in D), nerve (see N in E) and sweet glands (see SG in F). (G and H) Representative H&E sections from Gem9/LT tumors 
showing different areas with high necrosis. N = necrotic cells and L = living cells. (I) Volume of mammary tumors developed in mice (10 
mice/group) injected with HME/TERT, HME/TERT/LT, HME/TERT/geminin (i.e. Gem9), or HME/TERT/LT/geminin (i.e. Gem9/LT) 
cells. (J and K) Representative images showing the size (J) and the bloody appearance (K) of geminin overexpressing mammary tumors. 
Arrows show blood vessels. (L-N) Representative sections from geminin overexpressing mammary tumors stained with H&E showing 
normal (dashed arrows) and large (solid arrows) size nuclei. Sections also show increase blood vessels in these areas. (O) Density of blood 
vessels in areas containing tumor cells with normal size nuclei vs. areas with tumor cells with abnormal (large) size nuclei. (P) Volume of 
mammary tumors developed in mice (10 mice/group) injected with parental or geminin silenced MDAMB231 cells. Mice were kept on a 
Dox-supplemented water to induce geminin shRNAs. (Q) Representative Xenogene images at day 20 of subcutaneous tumors developed 
in mice injected with parental MDAMB231 (left) or MDAMB231/shGem1 (right) cells. Mice were kept on a Dox-supplemented water to 
induce geminin shRNA expression. Note the dramatic size difference in the luciferase signals.Oncotarget 2011; 2:  1011 - 1027 1020 www.impactjournals.com/oncotarget
These data, again reinforce the fact that overexpression of 
Y phosphorylated/activated geminin protects HME cells 
against cell death induced by AurB inhibitors (i.e. induces 
AurB drug resistance). 
To evaluate whether these effects are restricted to 
AurB inhibitors or can be seen with drugs that alter the 
integrity of the microtubules apparatus as well, HME 
and induced (72) Gem9 cells were treated with DMSO 
(control), Nocodazole (a microtubules depolymerizing 
agent) or Taxol (a microtubules stabilizing agent) for 
another 24h. FACS analysis showed that Nocodazole 
(Suppl. Figure 2G) or Taxol (Suppl. Figure 2H) treatment 
also triggered accumulation of normal HME cells in 
G2/M phase, followed by tetraploidy and then cell death. 
However, both treatments also had modest effect on 
geminin overexpression cells (Suppl. Figure 2C and 2D). 
Moreover, FACS analysis of Nocodazole treated 
uninduced and induced Gem9 cells labeled with PI/
Figure 7: Geminin overexpression in aggressive primary breast cancers. (A) Expression of geminin protein (upper) and mRNA 
(lower) in HME and several breast cancer cell lines. (B) Comparisons of geminin-positive (red bars) and -negative (green bars) in the 
test cohort (see text) using immunohistochemistry analysis. Blue bars show total number of tumors. (C and D) Representative images of 
geminin expression in normal (C) and invasive tumor (D) samples from the confirmation cohort. (D) Geminin mRNA level in breast cancer 
grade I (n=12) and grade III (n=78) samples. (E) Geminin mRNA level in metastasis < 5years and > 5years from diagnosis. Data in D and 
E were extrapolated from publicly available breast cancer gene expression microarray data set (vant’ Veer et al., 2002). Data represented 
as mean ± SD and p values are shown.Oncotarget 2011; 2:  1011 - 1027 1021 www.impactjournals.com/oncotarget
annexin V showed that in Nocodazole treated HME cells, 
75±5% of the cells were PI-/V-, 6±4% were PI+/V- and 
20±5% were PI-/V+ + PI+/V+ (Suppl. Figure 2C), whereas 
in Nocodazole treated induced Gem9 cells 78±6% of the 
cells were PI-/V-, 12±3% were PI+/V- and 10±2% were 
PI-/V+ + PI+/V+ (Suppl. Figure 2F). Overall, these data 
clearly show that overexpression of Y phosphorylated/
activated geminin protects against cell death induced 
by AurB inhibition, or drugs that alter the fidelity of the 
microtubules apparatus. 
Geminin overexpression promotes tumor 
formation in SCID mice
To determine the tumorigenic effect of geminin, 
in vivo, we attempted to develop tumors using geminin 
overexpressing HME cells in SCID mice. Five million 
luciferase expressing immortalized HME (with TERT) 
cells that express SV40-Large T (LT), inducible geminin 
(i.e. Gem9) or both (i.e. Gem9/LT, see also [26]) were 
mixed 1:1 with matrigel and injected either subcutaneously 
or in the mammary fat pad of 10 (per cell line) SCID 
mice. All mice were maintained on Dox-supplemented 
drinking water during the duration of the experiments. 
Tumor development was monitored weekly by Xenogen® 
imaging and all cell lines were detected in mice on day 1 
(Suppl. Figure 3, upper panels), but only Gem9/LT cells 
on day 30 and 60 (49 for mammary tumors, Suppl. Figure 
3, lower panels and data not shown). 
Geminin overexpressing cells formed subcutaneous 
tumors in 100% of the mice that were palpable at ~day 30, 
grow rapidly thereafter to reach ~1.5cm3 (the allowed size) 
by 9 weeks (Figure 6A). Dissected tumors were paraffin 
embedded, sectioned at 4µm and stained with H&E. 
Geminin-induced tumors showed signs of aggressiveness. 
For example, the subcutaneous tumors invaded mouse 
muscle (see M in Figure 6B) so much that tumor cells that 
were injected on the outside of the muscle were detected 
on the other side of the muscle surrounding the bone (see 
B in Figure 6C). These tumors also invaded the skin (see 
S in Figure 6D), the nerves (see N in Figure 6E) and the 
sweet glands (see SW in Figure 6F). Necrosis, the sign of 
aggressiveness and increased cancer cells’ proliferation, 
was prominent component in these tumors as well 
(examples are shown in Figure 6G and H). 
Mammary tumors also formed in 100% of the mice 
and were more proliferative/aggressive and grow even 
more rapidly (reached ~1.5cm3 in 7weeks only, Figure 6I). 
Like subcutaneous tumors, mammary tumors also were 
invasive. More importantly, in both models, we noticed 
the presence of large areas of the tumors containing cells 
with abnormally large size nuclei (compare cells marked 
with solid arrows to cells marked with dashed arrows in 
Figure 6L-N). We reasoned that such cells could form from 
mouse macrophages infiltrating into the tumors and fuse 
as in Langerhans giant cells, typical of a tuberculoma [27] 
or they are aneuploid cells generated by overexpression 
of Y phosphorylated/activated geminin. To distinguish 
between the two possibilities we immunohistochemically 
stained sections with an anti-human cytokeratin 5/6 
(CK5/6) or an anti-mouse F4/80 (recognizes a protein 
expressed by activated murine macrophages). While, 
some tumor cells with normal and large size nuclei stained 
positive for CK5/6 (Suppl. Figure 4A and arrows in Suppl. 
Figure 4C, respectively), none stained positive for F4/80-
negative (Suppl. Figure 4B and dashed arrows in Suppl. 
Figure 4D). The F4/80 antibody, however, stained mouse 
macrophages  infiltrated  into  the  tumors  in  the  same 
sections (see arrowheads in Suppl. Figure 4B and 4D). 
These geminin-induced tumors showed increased 
angiogenesis (see the bloody appearance denoted by 
arrows in Figure 6J and 6K). Analysis of H&E sections 
also  confirmed  increase  numbers  of  blood  vessels  in 
these tumors, especially in areas containing cells with 
abnormally large nuclei (see examples in Figure 6L-N). 
To determine the microvessel density, tumors sections 
were immunohistochemically stained with anti-mouse 
CD34 and microvessel density was determined as 
described previously [28]. In subcutaneous tumors 141±9 
vs. 15±3 vessels/mm3 (n=10, p<0.01) and in mammary 
tumors 152±8 vs. 13±2 vessels/mm3 (n=10, p<0.01) of 
microvessels were detected in areas with tumor cells with 
large size nuclei vs. areas with tumor cells with normal 
size  nuclei  (Figure  6O).  These  findings  indicate  that 
geminin overexpressing cells can induce host stromal cells 
to produce microvessels, and implies that aneuploid tumor 
cells attract more blood vessels than non-aneuploid cells, 
or that aneuploid cells are formed in areas with abundant 
blood supply. 
Geminin overexpression maintains the growth of 
mammary tumors in SCID mice
To determine whether geminin overexpression 
also maintains breast tumor growth in vivo, the very 
aggressive breast cancer cell line, MDAMB231 [29, 
30] that endogenously overexpress geminin (see Figure 
7A) was used to generate clones that express 3 different 
conditional geminin shRNAs or a GFP shRNA (as control). 
All cell lines including parental MDAMB231 cells were 
made to express luciferase (hereafter: MDAMB231/Luc, 
MDAMB231/Luc/shGem1, /shGem2, /shGem3 and /
shGFP). 
We injected 5x106 cells (mixed 1:1 with matrigel) 
of each of these clones either subcutaneously or in the 
2nd mammary fat pad of 10 SCID mice/cell line. Mice 
were maintained on Dox-supplemented drinking water. 
MDAMB231 cells are very aggressive cells indeed, tumors 
were palpable in all mice whether injected subcutaneously 
or in the mammary fat pad at day 4 and ranged in size Oncotarget 2011; 2:  1011 - 1027 1022 www.impactjournals.com/oncotarget
between 0.15-0.25cm3 (Figure 6P). By day 20 the size 
of the subcutaneous or mammary tumors developed by 
the MDAMB231 or MDAMB231/shGFP cells were so 
large that we had to sacrifice the mice (Figure 6P and 
6Q, left). In contrast, geminin silencing suppressed the 
growth of the MDAMB231 cells injected in the mammary 
gland. Tumors either remained at ~0.2cm3 (/shGem2, 
Figure 6P, blue line) throughout the experiment time (20 
days), increased to ~0.5cm3 before regressing to ~0.2 
cm3 (/shGem1, Figure 6P, green line), or grew slightly to 
~0.5cm3 (/shGem3, Figure 6P, pink line) by day 20. Five 
extra mice injected with /shGem1 cells were followed for 
80 days and tumors remained ~0.2cm3 (data not shown). 
Moreover, geminin silencing also suppressed the growth 
of MDAMB231 cells injected subcutaneously, in vivo 
(see example in Figure 6Q right). Taken together, these 
data suggest that although previous reports suggested a 
putative tumor suppressor function for geminin [11,12,31], 
we show here that when overexpressed in HME cells, 
geminin acts as an oncogene that promotes formation and 
maintenance of aggressive and aneuploid breast tumors, 
in vivo. 
Geminin is overexpressed in aggressive human 
mammary tumors
Geminin protein is overexpressed in cancer cells 
and predicts adverse clinical outcome in breast cancer 
[23,32,33]. To expand on these data, we examined the 
expression of geminin mRNA  and protein in breast 
tumor samples and cancer cell lines. We found that 
geminin protein (Figure 7A, upper) and mRNA (Figure 
7A, lower) are overexpressed in breast cancer cell 
lines. More importantly, we used the newly developed 
mouse monoclonal anti-geminin antibody (see [20]) to 
analyze geminin expression in primary tumor samples 
by immunohistochemistry. For these analyses we used 
two  cohorts  of  paraffin  embedded  tissue  microarrays 
(TMA) constructed in quadruplicate each containing one 
sample from a different region of the tissue/tumor at 4µm. 
The first was a “test cohort”, which was a commercial 
TMA (Biomax.us) that consisted of 66 normal or cancer 
adjacent, 180 cases of ductal carcinoma in situ (DCIS), 
100 cases of invasive breast cancers and 165 cases of 
metastatic breast cancers. The second was a “confirmation 
cohort” consisted of 326 breast cancer tumors of different 
stages, in addition to several disease-free adult tissues 
(e.g., kidney, liver, placenta and spleen) and normal breast 
tissues that were acquired from the Hawaiian Surveillance, 
Epidemiology and End Results (SEER) collection. 
Following immunohistochemical staining, analysis 
and scoring was done blindly by two pathologist and was 
as follows; 0 = no staining (<1% of the cells stained), 
1+ = weak (1-10% of the cells stained), 2+ = medium 
(10-50% of the cells stained), 3+ = strong (>50% of the 
cells  stained).  Staining  scores  ≤10%  were  considered 
negative tumors. In the test cohort, only 2 out of the 66 
normal/cancer adjacent tissues were geminin-positive 
(3%, Figure 7B and example in 7C), whereas 92 from 
the 180 DCIS (51%, Figure 7B), 61 out the 100 invasive 
(61%, Figure 7B and example in 7D) and 113 from the 
165 metastatic tumors (68%, Figure 7B) were geminin-
positive. These data suggest that geminin expression 
increases further with disease progression. Furthermore, 
on the confirmation cohort, several disease-free tissues, 
e.g., liver, placenta, Kidney and spleen showed high level 
of geminin (not shown). Furthermore, while normal breast 
tissue were geminin-negative, 188 from the 326 (~52%) 
of the breast tumor samples in this confirmation cohort 
stained positive for geminin. We also identified a set of 32 
Her2+ and 72 triple negative/basal like (TN/BL) tumors. 
In these tumors, 21 of the Her2+ tumors (~66%) and 41 of 
the TN/BL tumors (~57%) were geminin-positive tumors. 
The expression of geminin mRNA was also analyzed 
in several publicly available gene expression microarray 
data sets [34-36, please note that similar results were 
obtained using the other data sets and details of these 
analysis will be published elsewhere]. The data revealed 
that geminin mRNA is expressed at significantly higher 
levels in high-grade [n=78] compared to low-grade 
[n=12] breast tumors (p=3xe-4, Figure 7D), as well as in 
tumors that metastasized <5 years compared to >5 years 
from diagnosis (p=1.5xe-2, Figure 7E). High geminin 
mRNA was also detected in estrogen- (p=2.929xe-8, data 
not shown) and progesterone- (p=2.764xe-9, data not 
shown) receptor negative tumors, and in tumors carrying 
mutant BRCA1 (p=1.262xe-3, data not shown). In lymph 
node-positive (p=4.229xe-5, data not shown) and tumors 
showing increased angiogenesis (p=1.399xe-3, data not 
shown) geminin mRNA was also high.
Finally, to evaluate any genomic alteration in the 
geminin gene in breast cancers, a cohort of 150 breast 
patients DNA was analyzed with SNP analysis. No 
mutation, insertion, deletion or any other alterations was 
found in any of the tumors in this cohort (D. Igelhart, 
personal communication). Overall the data show that 
overexpression of wild type geminin induces cytokinesis 
failure and formation of aneuploid cells, in part, by 
suppressing AurB kinase. Geminin overexpression also 
prevents death of the resultant tetraploid/aneuploid 
cells, thus they can propagate and increase chances for 
the development of aggressive breast cancer. Indeed, 
geminin is overexpressed in the most aggressive types of 
breast cancers, e.g., Her2+ and TN/BL and is associated 
with adverse prognosis in invasive breast cancer. Thus, 
inhibiting geminin expression and/or activity could 
increase the efficacy of these drugs in a clinical setting.Oncotarget 2011; 2:  1011 - 1027 1023 www.impactjournals.com/oncotarget
DISCUSSION
In addition to binding to chromosomes in G2/M/early 
G1 cells [20,22], we here show that Y phosphorylated 
(simultaneously on all 3 tyrosine residues)/activated 
geminin is also localized to centrosomes, spindle, cleavage 
furrow and midbody during mitosis. Other proteins that 
show similar distribution during mitosis are mitotic 
checkpoint proteins, such as Polo kinase (Plk1) and the 
CPC (AurB, INCENP, survivin, and borealin, reviewed 
in [7]). Silencing of geminin arrested cytokinesis [20], 
while its overexpression triggered aneuploidy by inducing 
cytokinesis skipping. Interestingly, many proteins 
involved in proper cytokinesis are also required for 
accurate chromosome segregation [2], and interference 
with the expression or regulation of these components may 
lead to both chromosome missegregation and cytokinesis 
failure. We propose that geminin is a novel chromosome 
segregation and proper cytokinesis regulator [20,22]. 
Aneuploidy is a hallmark of aggressive breast 
cancers [37]. Identification of molecules and mechanisms 
that  lead  to  aneuploidy  will  be  beneficial  in  designing 
new therapies against breast cancer metastasis. Tetraploid 
cells (the precursors of aneuploid cells) can arise from 
diploid cells through cell fusion, endo-reduplication 
or cytokinesis failure (reviewed in [1-3]). AurB plays 
important roles in both early and late stages of cytokinesis, 
by phosphorylating a wide variety of proteins essential 
for different steps of these processes. AurB inhibition 
even at very late stages of cytokinesis induces furrow 
regression [38], suggesting that AurB positively regulates 
abscission in mammalian cells [6,39]. It is thus possible to 
suggest that geminin overexpression generates aneuploid 
cells by suppressing AurB activity leading to abscission 
failure and furrow regression. The fact that activation of 
AurB requires binding to INCENP during mitosis and 
that geminin also binds to AurB during mitosis suggest 
that the two proteins perhaps compete for AurB binding. 
At normal level, INCENP perhaps binds AurB first and 
induces its autophsophorylation and activation, when 
geminin is overexpressed it binds AurB first and prevents 
its binding to INCENP and thus activation. 
Intriguingly, AurB activity is also required for 
disassemble of the merotelic chromosome attachment 
occurs in DNA damaged cells [5,40]. In our recent study 
[22], we showed that geminin overexpression induced 
TopoIIα-dependent  chromosome  breakages  [22].  It  is 
possible that geminin inactivation of AurB increases 
the chances for segregation of such damaged, lagging 
chromosomes, the likelihood of cytokinesis failure, and 
formation of tetraploid/aneuploid cells. In keeping with 
this, treating leukemia cells with the AurB kinase specific 
inhibitor; AZD1152 was shown recently to induce 
accumulation of cells with >4N DNA content. However, 
these cells proceeded to die, unlike the >4N cells generated 
after geminin overexpression (even in tumors) perhaps 
because geminin overexpression also induced expression 
and activation of several pro-survival factors in these cells. 
Because multiple Bcl-2 anti-apoptotic members were 
found highly overexpressed in geminin overexpressing 
cells, we propose that geminin plays an important role in 
maintaining survival of aneuploid, chemo-resistant cells 
and that overcoming geminin overexpression-induced 
breast cancers, in vivo will require co-antagonism of 
several Bcl-2 anti-apoptotic proteins. It is perhaps possible 
to suggest that in geminin overexpressing tumors a model 
of co-antagonism such that described recently by Lang et 
al. [41] has better therapeutic effect than inhibition of each 
protein individually [41]. 
Complete loss of the spindle checkpoint is lethal [42-
44]. However, partial loss, such as in mice lacking only 
one copy of checkpoint proteins such as Mad2, BubR1 or 
CENP-E has no effect [42, 44-46]. Interestingly, reduction 
of expression of any of these genes triggered aneuploidy 
and increased rate of tumorigenesis [37]. It is possible 
that as yet unidentified spindle checkpoint protein(s) are 
suppressed in geminin overexpressing aneuploid tumor 
cells. 
The fact that HME cells overexpressing geminin 
form tumors in SCID mice suggest that unlike what is 
previously thought, when overexpressed, geminin behaves 
as a genuine oncogene that induces DNA damage [22] 
and survival of DNA damaged cells (this study) leading 
to formation of aneuploid cells ([22], and this study). Not 
surprising geminin is overexpressed in ~50% of all breast 
tumors analyzed and to even higher degrees in two of the 
most aggressive subtypes, Her2+ and TN/BL tumors. In 
the mouse or in human, geminin overexpressing tumors 
also showed increased neo-angiogenesis suggesting that 
these tumors stimulate the surrounding mouse or human 
stroma to generate blood vessels. Our data combined 
support the view that geminin is a novel breast cancer 
therapeutic target. Geminin inhibition, in vivo, is also 
expected to increase the efficacy of existing drugs such 
as Taxol, doxorubicin and AurB inhibitors. Until specific 
geminin inhibitor is identified, it is perhaps possible to 
treat these tumors with anti-angiogenic drugs. 
METHODS
Cell Culture and drug treatment. Cell Culture 
and drug treatment
Breast cancer cell lines were maintained in RPMI 
medium (Invitrogen) supplemented with 10% FBS and 
antibiotics. HME cells maintenance was described earlier 
[20,22]. Cells were treated with 5µM ZM477493 (Toronto 
Research Chemicals Inc.), 100ng/ml colcemid (Sigma), 
250ng/ml Nocodazole (Sigma), 10µM Taxol (Sigma). 
PI or FITC-conjugated anti-BrdU FACS analysis was Oncotarget 2011; 2:  1011 - 1027 1024 www.impactjournals.com/oncotarget
performed as in [20]. Annexin-V was performed according 
to manufacturer’s instructions (BD biosciences, 556547). 
Antibodies
The antibody against geminin is a monoclonal 
produced by our laboratory [20], rabbit anti-gamma-
tubulin (abcam, ab11320), mouse anti-Myc-tag (Santa 
Cruz, 9E10, SC-40), mouse anti-actin (Calbiochem, cat. 
# CP01-1E2), mouse anti-His (Invitrogen, 46-0284), 
rabbit anti-p-(S10)-H3 (D2C8, abcam, ab3465), rabbit 
anti Aurora B (abcam, ab2254), rabbit anti-p-T232-
Aurora B (abcam, ab61074), rabbit anti-INCENP (abcam, 
ab12183), anti-CD34 [MEC 14.7] - hematopoietic stem 
cell marker (ab8158), mouse anti-cytokeratin 5/6 (abcam, 
ab17133) and rat anti-F 4/80 (abcam, ab6640), rabbit IgG 
isotype control (abcam, ab 4340).
Transit and stable transfection
Twenty µg of pcDNA3.1-Myc-wild type, Y98A, 
Y111A or Y150A geminin variants were transfected into 
50% confluence HME cells using Lipofectamine PLUS 
reagent (Invitrogen) in 8 chambers slides. Clontech kit 
Rev-Tre/Tet-ON inducible system was used. Wild type 
geminin  cDNA  was  amplified  from  HME  total  RNA 
using primers that amplify the whole cDNA including 
portions from the 5`- and the 3`-UTRs. Using site-directed 
mutagenesis kit (NEB) and suitable primers, the Rev-Tre-
GemY98A, Y111A or Y150A were generated. GST-H3 
expression plasmid was also generated using PCR 
technique in the pGEX-4T2. 
Virus and protein expression
Retroviruses production was done using standard 
protocols. After infection 10 hygromycin selected 
clones were tested for the expression of the exogenous 
geminin using anti-His Western blot. The GST-fused H3 
was expressed in competent bacteria “One shot BL-21 
star (DE3)pLysS” (Invitrogen), induced with IPTG and 
purified on Glutathione SepharoseTM 4B beads (GSSH), 
and eluted from the beads using 10mM of Glutathione in 
50mM Tris–HCl pH 8.0.
Real time RT/PCR Assays
Total RNA was isolated after treatments using 
TRIzol reagent (Invitrogen) and treated with a DNA-
free kit (Ambion, Austin, TX) to eliminate genomic 
DNA contamination. Quantitative RT/PCR analyses 
were performed according to standard protocols using 
iQ Sybergreen Supermix using the primers; Geminin: 
forward 5`-CGGGA TCCAT GAATC CCAGT ATGAA 
GCAGA AACAA GAA-3` and reverse 5`-ACGCG TCGAC 
TCATA TACAT GGCTT TGCAT CCGTA-3’, GAPDH: 
forward 5`-GGACC TGACC TGCCG TCTAG-3` and 
reverse 5`-TGGTG CTCAG TGTAG CCCAG-3`.
Triplicate CT values were analyzed in Microsoft 
Excel  using  the  comparative  CT  (∆∆CT)  method  as 
described by the manufacturer (Applied Biosystems). The 
amount of target (2-∆∆CT) was obtained by normalization 
to an endogenous reference (18S RNA) and relative to a 
calibrator.
Chromatin and soluble nuclear extracts 
purification and immunoprecipitation
Chromatin and soluble nuclear extracts purification 
and immunoprecipitation. Protocol described earlier in 
[20] was used.
Metaphase Spread
A 100ng/ml colcemid was added directly to culture 
dish and dish was swirled, incubated for 1hrs. Cells were 
then trypsinized and washed and gently resuspended in 
PBS. A 10 ml of 0.075M KCl was drop wise added and 
the cells were incubated at 37ºC (in a water bath) for 
5-10mins. Cells were then centrifuge at 900rpm for 5 
minutes and KCl was removed. A5 ml of freshly prepared 
fixative (3:1 Methanol/Acetic acid) was added drop wise 
to the cells and carefully mixed. Cells were centrifuge at 
900rpm for 5 minutes and the fixative was removed. This 
step was repeated 2 more times. Finally all but 300μl of 
the fixative media was removed and cells were dropped 
from  ~18  inches  onto  angled,  humidified  microscope 
slide. Slides were air-dry for at least 10 mins and cells 
were stained with PI or Giemsa.
RNA Interference Experiment
Geminin  siRNA was described in [20,22]. And 
transfection of siRNAs in HME cells was performed 
using Oligofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. 
TUNEL detection protocol
The Fluorescein FragELTM DNA Fragmentation 
Detection kit was used according to the supplier 
(Calbiochem) protocol. 
Soft Agar Colony Formation Assay
A mixture of equal volumes of the 1% Nobel agar 
(Difco) and HME medium were layer on a 6 well plates Oncotarget 2011; 2:  1011 - 1027 1025 www.impactjournals.com/oncotarget
and allow to settle. A 5,000 cells was mixed with 0.7% 
of the same agar prepared in pre-warmed (~40ºC) HME 
medium were layer on the agar dishes and incubate at 
37ºC in humidified incubator for 2-3 weeks in the presence 
or absence of 2µg/ml Dox. Cells were then stained with 
0.5ml of 0.005% Crystal Violet for >1 hour, and colonies 
were counted under light microscope. HEK293T cells 
were used as positive control and IMR90 cells as negative 
control. 
Tissue samples and immunohistochemical 
analysis of paraffin-embedded tumor samples
Tissue microarrays were purchased from Biomax.
us, or were constructed at the University of Hawaii 
Cancer Center using tissue from the SEER (Surveillance 
Epidemiology and End Results) collection. All human 
tumor samples experiments were approved by a University 
of Hawaii IRB committee. Form tumors generated in 
mice and embedded in paraffin 4µm sections were also 
prepared. For all antibodies used in this study, the antigen 
retrieval technique used was carried out by microwave 
treatment of the slides in sodium citrate buffer (pH 6.0) 
for 20min.
Subcutaneous and mammary tumorigenicity 
assay
All animal experiments were approved by the 
University of Hawaii IACUC committee and University 
of Mississippi Medical Center IACUC committee. Six- 
to eight-week-old anaesthetized immune-compromised 
athymic SCID (NOD.CB17-Prkdcscid/J, Jackson 
Laboratory) mice were injected with HME cells (5 x106) 
resuspended in 200µl of HME medium/matrigel (1:1) 
using a 25-gauge needle. Tumor initiation was defined as 
the time when tumors were 3mm in diameter. Mice were 
sacrificed when the tumors grew to >1.5 cm in diameter or 
after 12wk of monitoring. Tumor volume was calculated 
with  the  formula  4/3πr3 (where r is the tumor radius). 
At the end of the experiments tumors were dissected 
out, weighed and then fixed in formalin, cut at 4µm for 
histological and immunohistochemical analysis.
In Vivo measurement and imaging of subcutaneous 
or mammary tumors
Tumor formation was analyzed with IVIS luciferase 
machine (Xenogen) weekly and tumor size was measured 
every 3rd day by caliper (Life Sciences instruments). 
To analyze tumor formation using the in vivo system, 
mice were i.p. injected using 30G needle with 100µl of 
D-luciferin solution (Xenogen) prepared at 15mg/mL in 
PBS. Mice were then anesthetized using a mix of oxygen 
and isoflurane gas. Anesthetized animals were maintained 
sleep during the imaging procedures by placing the animal 
right side (injection side) up and its nose in a nose cone with 
a flow of anesthesia gas and take a picture of the tumors. 
Examples are shown in supplementary information.
Statistical Analysis
Comparisons of treatment outcomes were tested for 
statistical differences using the Student t-test for paired 
data. The association of mRNA transcript expression with 
various clinico-pathologic parameters was also analyzed. 
Statistical significance was assumed at a p-value are * ≤ 
0.05, ** ≤ 0.01 and *** ≤ 0.001.
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